RxDoctor Payments DataLook up a doctor →

David Bear, DO

Neurology · Pensacola, FLNPI 1689643645

Payments from drug & device makers

$10,066,799in general payments, 2019–2025

Across 2,208 payments — averaging $4559.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$7.4M
  • Novartis$2M
  • Lilly USA, LLC$246K
  • Sage Therapeutics, LLC$110K
  • E.r. Squibb & Sons, L.L.C.$95K
  • AbbVie$89K
  • plus $188K from 54 others
$181,341in research payments, 2019–2025

Across 32 payments — averaging $5666.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$154K
  • Ipsen Innovation$27K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly82$7,365,713
Novartis142$1,973,287
Lilly USA, LLC330$245,589
Sage Therapeutics, LLC2$109,904
E.r. Squibb & Sons, L.L.C.8$94,636
AbbVie(2 entities)347$89,294
Amgen(2 entities)83$41,482
Lundbeck LLC73$30,022
Teva Pharmaceuticals USA, Inc.81$24,011
Impel Pharmaceuticals Inc.49$15,780
Biohaven Pharmaceuticals, Inc.25$15,529
Pfizer145$14,328
Biohaven Pharmaceutical Holding Company Ltd.21$10,137
Axsome Therapeutics, Inc.21$8,332
Jazz Pharmaceuticals Inc.93$8,246
Ipsen Innovation3$3,611
Eisai Inc.38$2,792
MDD US Operations, LLC19$1,247
SK Life Science, Inc.52$1,103
Biogen51$807
EMD Serono, Inc.44$762
UCB, Inc.34$666
Genentech USA, Inc.31$590
AstraZeneca(2 entities)23$508
Acorda Therapeutics, Inc23$448
Sunovion Pharmaceuticals Inc.30$447
Sanofi12$407
Catalyst Pharmaceuticals, Inc.16$397
Supernus Pharmaceuticals, Inc.27$365
Bristol Myers Squibb12$349
Acadia Pharmaceuticals Inc19$344
Otsuka America Pharmaceutical, Inc.15$319
CSL Behring9$308
Argenx US, Inc.12$305
Octapharma USA, Inc.12$298
Adamas Pharmaceuticals, Inc.11$228
Grifols USA, LLC11$228
Merz Pharmaceuticals, LLC8$216
Neurocrine Biosciences, Inc.11$201
Takeda Pharmaceuticals U.S.A., Inc.12$201
Greenwich Biosciences, Inc.9$181
Upsher-smith Laboratories LLC12$181
Amneal Pharmaceuticals LLC11$179
Merz North America, Inc.6$173
Mallinckrodt Hospital Products Inc.6$152
Averitas Pharma Inc.7$140
Alnylam Pharmaceuticals Inc.7$139
Merck9$138
GE HealthCare6$134
Philips North America LLC4$119
Avadel CNS Pharmaceuticals, LLC5$116
Harmony Biosciences LLC6$109
Neurelis, Inc.5$107
Inspire Medical Systems, Inc.3$102
Livanova USA, Inc.6$100
Revance Therapeutics, Inc.4$93
Kyowa Kirin, Inc.5$86
Mallinckrodt Enterprises LLC5$86
Xeris Pharmaceuticals, Inc.5$84
Tanabe Pharma America, Inc.5$84

How this compares

$10,066,799 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida →

Medicare billing

Part B allowed, 2024
$1,283,391
Medicare patients
1,569
Services billed
107,831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Pensacola

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →